Clinical impact of hypomagnesemia induced by necitumumab plus cisplatin and gemcitabine treatment in patients with advanced lung squamous cell carcinoma: a subanalysis of the NINJA study
Shigeru Tanzawa(Teikyo University), Nobuhiko Seki(Teikyo University), Fumihiko Kinoshita(Kyushu University), Anna Hayashi(Nippon Medical School), Kosuke Tsuruno(Aso Iizuka Hospital), Kazuhiro Asada(Shizuoka General Hospital), Kiichiro Ninomiya(Okayama Shoka University), Hiroshi Kuraishi(Nagano Red Cross Hospital), Eisaku Miyauchi(Tohoku University), Akira Nakao(Hiroshima University), Kakuhiro Yamaguchi(Hiroshima University Hospital), Teppei Yamaguchi(Aichi Cancer Center), Toshihiro Misumi(Yokohama City University), Hiroshi Tanaka(Hachinohe Gakuin University), Hiroshige Yoshioka(Harbin Medical University), Yosuke Kawashima(Sendai Kousei Hospital), Akihito Kubo(Aichi Medical University), Ken Yoshihara(Shimane University), Yuki Misumi(Yokohama Municipal Citizen's Hospital), Yasunori Murata(Ichinomiya Kenshin College), Go Saito(Chiba University), Akihiko Miyanaga(Nippon Medical School), Toshihiko Yokoyama(Japanese Red Cross Nagoya Daiichi Hospital), Toshiyuki Kozuki(Shikoku Cancer Center), Yukihiro Umeda(University of Fukui), Kazuya Nishii(Okayama University), Yuki Sato(Kobe City Medical Center General Hospital), Nobuhisa Ishikawa(The University of Tokyo), Shunichi Sugawara(Sendai Kousei Hospital), Masafumi Nojiri(Kanazawa Medical University), Kazuki Hashimoto(Toneyama National Hospital), Takatoshi Fujishita(National Hospital Organization Kyushu Cancer Center), Akito Hata, Ryoichi Honda(Asahi General Hospital), Masahide Mori(Toneyama National Hospital), Kana Watanabe(Miyagi Prefectural Hospital Organization), Takahisa Kawamura(Osaka International Cancer Institute), Masafumi Takeshita, Satoshi Watanabe(Niigata University Medical and Dental Hospital)
Cited by 3
Related Papers
Gefitinib or Chemotherapy for Non–Small-Cell Lung Cancer with Mutated EGFR
|New England Journal of Medicine|2010|5.6k
Pembrolizumab plus Chemotherapy for Squamous Non–Small-Cell Lung Cancer
|New England Journal of Medicine|2018|3.7k
Adjuvant atezolizumab after adjuvant chemotherapy in resected stage IB–IIIA non-small-cell lung cancer (IMpower010): a randomised, multicentre, open-label, phase 3 trial
|The Lancet|2021|1.5k
Osimertinib with or without Chemotherapy in <i>EGFR</i> -Mutated Advanced NSCLC
|New England Journal of Medicine|2023|695